Royal Bank of Canada Begins Coverage on Catalent (CTLT)
Royal Bank of Canada started coverage on shares of Catalent (NYSE:CTLT) in a research report report published on Wednesday morning, Marketbeat reports. The firm issued an outperform rating and a $46.00 target price on the stock.
CTLT has been the subject of a number of other research reports. BidaskClub raised Catalent from a sell rating to a hold rating in a research note on Wednesday, August 16th. Wells Fargo & Company raised their price target on Catalent from $39.00 to $43.00 and gave the stock an outperform rating in a research note on Wednesday, September 20th. Bank of America reaffirmed a buy rating and issued a $45.00 price target (up previously from $40.00) on shares of Catalent in a research note on Wednesday, September 20th. Piper Jaffray Companies reissued a buy rating and set a $45.00 price objective on shares of Catalent in a research report on Tuesday, August 29th. Finally, Jefferies Group reissued a hold rating and set a $38.00 price objective (up previously from $35.00) on shares of Catalent in a research report on Tuesday, August 29th. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of Buy and an average price target of $44.44.
Catalent (NYSE:CTLT) opened at $41.12 on Wednesday. The company has a quick ratio of 2.49, a current ratio of 2.91 and a debt-to-equity ratio of 2.01. Catalent has a fifty-two week low of $25.51 and a fifty-two week high of $43.39. The stock has a market cap of $5,322.35, a P/E ratio of 28.01, a PEG ratio of 2.57 and a beta of 1.41.
Catalent (NYSE:CTLT) last issued its earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.01. Catalent had a net margin of 5.01% and a return on equity of 23.97%. The firm had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. During the same quarter last year, the business earned $0.16 earnings per share. The business’s revenue was up 23.0% on a year-over-year basis. research analysts forecast that Catalent will post 1.46 EPS for the current fiscal year.
In other news, Director Uwe Roehrhoff purchased 7,500 shares of the business’s stock in a transaction on Tuesday, November 21st. The stock was acquired at an average cost of $39.22 per share, for a total transaction of $294,150.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in CTLT. Zions Bancorporation purchased a new position in shares of Catalent during the 3rd quarter valued at about $100,000. Acrospire Investment Management LLC lifted its position in shares of Catalent by 72.2% during the 2nd quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after buying an additional 1,300 shares in the last quarter. Quantbot Technologies LP lifted its position in shares of Catalent by 110.7% during the 2nd quarter. Quantbot Technologies LP now owns 3,434 shares of the company’s stock valued at $120,000 after buying an additional 1,804 shares in the last quarter. Fortaleza Asset Management Inc. purchased a new position in shares of Catalent during the 3rd quarter valued at about $164,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Catalent by 12.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,043 shares of the company’s stock valued at $177,000 after buying an additional 559 shares in the last quarter. Institutional investors and hedge funds own 99.49% of the company’s stock.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with Analyst Ratings Network's FREE daily email newsletter.